ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW MEDICAL, INC. (NASDAQ:WENA), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces a strategic partnership with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of Japan's Okinawa Research Center for Longevity Science (ORCLS) for the research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases.
ANEW MEDICAL, INC.納斯達克股票代碼：WENA）是一家專門研究神經系統和年齡相關疾病的新型疾病改善療法和專業診斷的生物製藥公司。該公司宣佈與日本沖繩長壽科學研究中心（ORCLS）的鈴木誠博士、克雷格博士和布拉德利·威爾科克斯博士、理查德·阿爾索普博士和島袋道雄建立戰略合作伙伴關係，研究和開發ANEW的專利Klotho基因療法，以增強療法延長壽命，減少與年齡有關的疾病。
'Blue Zones', as coined by National Geographic explorer and journalist Dan Buettner, are located in Ikaria, Greece; the Ogliastra Region of Sardinia; the Nicoya Peninsula in Costa Rica; and Loma Linda, California.
'“藍區”正如《國家地理》探險家兼記者丹·布特納所創造的那樣，位於希臘的伊卡里亞、撒丁島的奧利亞斯特拉地區、哥斯達黎加的尼科亞半島和加利福尼亞的洛馬琳達。
Okinawa, the original 'Blue Zone', has been the focus of nearly five decades of groundbreaking research by ORCLS, leading to the discovery of other "longevity hotspots" - across the world. These areas are characterized by high concentrations of people who live to exceptional ages, while maintaining good health. Preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform, may contribute to longevity and provide protection against neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD) and Parkinson's Disease (PD). Remarkably, Okinawans have among the lowest prevalence rates of AD globally.
沖繩，原版'藍區'，一直是ORCLS近五十年來開創性研究的重點，這促成了世界各地其他 “長壽熱點” 的發現。這些地區的特點是活到特殊年齡的人群高度集中，同時保持良好的健康。初步數據表明 alpha-klotho 人類版 Klotho 基因及其分泌的α-Klotho蛋白異構體可能有助於延長壽命，並提供對神經退行性疾病的保護，例如肌萎縮性側索硬化（ALS）、阿爾茨海默氏病（AD）和帕金森氏病（PD）。值得注意的是，沖繩人是全球AD發病率最低的國家之一。
ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders including ALS, AD and PD. The collaboration with ORCLS is part of ANEW's research program on the extended life expectancy in Okinawa, Japan, which is renowned for its comparatively high number of people who live extremely long and healthy lives, many reaching 100 years and more.
ANEW的使命是在未得到滿足的醫療需求領域提供變革性的蛋白質、細胞和基因療法，特別是針對高度流行的神經退行性疾病和年齡相關疾病，包括ALS、AD和PD。與ORCLS的合作是ANEW在日本沖繩延長預期壽命的研究計劃的一部分。日本沖繩以相對較多的人口壽命極長和健康而聞名，許多人壽命達到100歲甚至更長。
ANEW is developing a groundbreaking portfolio of cell and gene-based therapeutics targeting the Klotho gene for potential treatment of debilitating neurodegenerative diseases. The Company holds a portfolio of novel intellectual property in major markets and is advancing clinical development.
ANEW正在開發突破性的基於細胞和基因的療法產品組合，其目標是 Klotho 可能治療使人衰弱的神經退行性疾病的基因。該公司在主要市場擁有一系列新型知識產權，並正在推進臨床開發。